Traders should monitor the progress of the Phase 2b study and subsequent development milestones, as the success of NV-5138/SPN-820 will determine the realization of up to $350 million in potential payments and the future value of this acquisition for Supernus. The non-compete clause reduces competitive risk.
Price Chart
Executive Summary
Supernus Pharmaceuticals completed the acquisition of NV-5138/SPN-820 assets from Navitor Pharmaceuticals, including intellectual property and regulatory materials. The deal is structured with a $350 million potential value through milestone payments tied to development, regulatory, and commercial success, plus Supernus completing a Phase 2b study. This acquisition expands Supernus's CNS pipeline in mental health disorders.
Key Financial Metrics
Key Facts
- Supernus Pharmaceuticals (SUPN) completed the acquisition of assets related to the compound NV-5138/SPN-820 from Navitor Pharmaceuticals.
- The acquisition includes intellectual property, inventory, regulatory and clinical materials, permits, data, records, and goodwill related to the compound.
- The purchase price consists of Supernus completing a Phase 2b study and up to $350 million in milestone payments.
- Milestone payments are contingent on development, regulatory, and commercial achievements.
- Supernus has the right to cease development if the Phase 2b study is not successful.
- The deal includes a five-year non-compete for key Navitor personnel.
- Navitor retained the Whitehead License and certain other assets not part of the transaction.
Financial Impact
Up to $350 million in contingent milestone payments based on future development, regulatory, and commercial success.
Risk Factors
- The Phase 2b study may not be successful, leading Supernus to cease development.
- The $350 million in milestone payments are contingent and may not be realized.
- Development, regulatory, or commercial success is not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040497 |
| Document: tm2611273d1_8k.htm | 0001104659-26-040497 |
| Document: 0001104659-26-040497-index-headers.html | 0001104659-26-040497 |
| Document: 0001104659-26-040497-index.html | 0001104659-26-040497 |
| Document: 0001104659-26-040497.txt | 0001104659-26-040497 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.60 (+2.68%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.60 (−10.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access